Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Curium to acquire Lantheus in all-cash deal worth up to $8bn
CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.
Prostate Cancer
-
04 Aug 2026
-
24 Aug 2023
FDA grants priority review to Pfizer and Astellas’ sNDA for XTANDI
The US Food and Drug Administration (FDA) has accepted and granted priority review to Pfizer and Astellas Pharma’s supplemental New Drug Application (sNDA) for XTANDI (enzalutamide) to treat non-metastatic castration-sensitive prostate cancer (nmCSPC) patients with high-risk biochemical recurrence (BCR).